JB Pharma does not see US policy impact on its lozenges-centric CDMO business
For the financial year ended March 31, 2025, JB Pharma posted a revenue of ₹3,918 crore as compared to ₹3,484 crore in FY23-24, up 12% | Photo Credit: Dado Ruvic With lozenges accounting for about 80 per cent of JB Chemicals & Pharmaceuticals’ contract …